WO2005072826A3 - Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection - Google Patents

Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection Download PDF

Info

Publication number
WO2005072826A3
WO2005072826A3 PCT/US2005/001710 US2005001710W WO2005072826A3 WO 2005072826 A3 WO2005072826 A3 WO 2005072826A3 US 2005001710 W US2005001710 W US 2005001710W WO 2005072826 A3 WO2005072826 A3 WO 2005072826A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
compositions
pathogenic infection
treat pathogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/001710
Other languages
French (fr)
Other versions
WO2005072826A2 (en
Inventor
Daniel Kalman
William Gerard Bornmann
Melanie Anne Sherman
Patrick Michael Reeves
Alyson Irene Swimm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Priority to DE602005023587T priority Critical patent/DE602005023587D1/en
Priority to AU2005209231A priority patent/AU2005209231B8/en
Priority to JP2006551238A priority patent/JP5520433B2/en
Priority to EP05705915A priority patent/EP1725295B1/en
Priority to CA2554201A priority patent/CA2554201C/en
Priority to AT05705915T priority patent/ATE481134T1/en
Publication of WO2005072826A2 publication Critical patent/WO2005072826A2/en
Publication of WO2005072826A3 publication Critical patent/WO2005072826A3/en
Anticipated expiration legal-status Critical
Priority to US12/969,659 priority patent/US8765777B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compositions and methods are provided for using tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using Abl-family tyrosine kinase inhibitors to treat pathogenic infection are provided. Infections to be treated according to the present invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.
PCT/US2005/001710 2004-01-21 2005-01-20 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection Ceased WO2005072826A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE602005023587T DE602005023587D1 (en) 2004-01-21 2005-01-20 COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS
AU2005209231A AU2005209231B8 (en) 2004-01-21 2005-01-20 Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
JP2006551238A JP5520433B2 (en) 2004-01-21 2005-01-20 Compositions and uses of tyrosine kinase inhibitors for treating pathogen infections
EP05705915A EP1725295B1 (en) 2004-01-21 2005-01-20 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
CA2554201A CA2554201C (en) 2004-01-21 2005-01-20 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
AT05705915T ATE481134T1 (en) 2004-01-21 2005-01-20 COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS
US12/969,659 US8765777B2 (en) 2004-01-21 2010-12-16 Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US53796004P 2004-01-21 2004-01-21
US60/537,960 2004-01-21
US55368104P 2004-03-16 2004-03-16
US60/553,681 2004-03-16
US61420304P 2004-09-29 2004-09-29
US60/614,203 2004-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10586382 A-371-Of-International 2005-01-20
US34376408A Continuation 2004-01-21 2008-12-24

Publications (2)

Publication Number Publication Date
WO2005072826A2 WO2005072826A2 (en) 2005-08-11
WO2005072826A3 true WO2005072826A3 (en) 2006-04-20

Family

ID=34831196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001710 Ceased WO2005072826A2 (en) 2004-01-21 2005-01-20 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Country Status (8)

Country Link
US (1) US8765777B2 (en)
EP (3) EP2260849A1 (en)
JP (2) JP5520433B2 (en)
AT (1) ATE481134T1 (en)
AU (1) AU2005209231B8 (en)
CA (1) CA2554201C (en)
DE (1) DE602005023587D1 (en)
WO (1) WO2005072826A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217033B2 (en) 2007-01-19 2012-07-10 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072826A2 (en) 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
BRPI0511805A (en) 2004-06-04 2008-01-15 Bioniche Life Sciences Inc use of imatinib to treat liver disorders and viral infections
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
WO2007002441A1 (en) * 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
ES2318616T3 (en) * 2006-06-01 2009-05-01 Cellzome Ag METHODS FOR THE IDENTIFICATION OF MOLECULES THAT INTERACT WITH ZAP-70 AND FOR THE PURIFICATION OF ZAP-70.
EP2471529A3 (en) 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc Heterocyclic compounds and uses thereof
JP5559043B2 (en) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド Novel heterocyclic compounds and uses thereof
JP5710251B2 (en) * 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Novel heterocyclic compounds and uses thereof
JP6166534B2 (en) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Novel regulatory proteins and inhibitors
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
HK1206338A1 (en) 2012-05-22 2016-01-08 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
US9487500B2 (en) 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
EP2769722A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6576325B2 (en) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー Heteroaryl compounds and their use
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
JP6799201B2 (en) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． Aerosol Tyrosine Kinase Inhibitor Compounds and Their Use
EP2905024A1 (en) * 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
CN106459063A (en) 2014-04-11 2017-02-22 北卡罗来纳-查佩尔山大学 MerTK-specific pyrimidine compounds
US10537574B2 (en) 2015-09-16 2020-01-21 Emory University Use of kinase inhibitors to manage tuberculosis and other infectious diseases
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2020232238A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
CN114340733A (en) * 2019-09-04 2022-04-12 加利福尼亚大学董事会 Regeneration of connective tissue function and phenotype by Npas2 inhibition
CN114081890B (en) * 2020-07-04 2023-06-02 中国医学科学院医药生物技术研究所 Application of pyrimidinone derivative in resisting tubercle bacillus infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2003035049A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
US6596746B1 (en) * 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2004026311A2 (en) * 2002-09-18 2004-04-01 Institut Gustave Roussy (Igr) Use of specific inhibitors of tyrosine kinases for immunomodulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (en) 1927-03-29 1929-09-30 В.С. Григорьев Anthracene cleaning method
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US4439089A (en) 1978-10-12 1984-03-27 Dresser Industries, Inc. Boom arm with rock deflection feature
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (en) 1994-11-14 1997-06-28 Warner Lambert Co 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION.
WO1999055335A1 (en) 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
JP2004520007A (en) * 2000-08-01 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Gene expression profile of KSHV infection and method of treating KSHV infection
JP2004519422A (en) * 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2- (4-Pyridyl) amino-6-dialkoxyphenylpyrido [2,3-d] pyrimidin-7-one
AU9458401A (en) 2000-09-20 2002-04-02 Ortho Mcneil Pharm Inc Pyrazine derivatives as modulators of tyrosine kinases
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
CA2432870A1 (en) 2000-12-22 2002-07-25 Ronghui Lin Substituted triazole diamine derivatives as kinase inhibitors
GB0125659D0 (en) 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
US7384907B2 (en) 2002-12-13 2008-06-10 Duke University Method of treating infection with ABl tyrosine kinase inhibitors
WO2005003325A2 (en) * 2003-03-11 2005-01-13 Dana Farber Cancer Institute Inhibition of viral pathogenesis
WO2005072826A2 (en) 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0511805A (en) * 2004-06-04 2008-01-15 Bioniche Life Sciences Inc use of imatinib to treat liver disorders and viral infections
WO2007002441A1 (en) 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
EP2471529A3 (en) 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
US6596746B1 (en) * 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2003035049A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
WO2004026311A2 (en) * 2002-09-18 2004-04-01 Institut Gustave Roussy (Igr) Use of specific inhibitors of tyrosine kinases for immunomodulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DORSEY J F ET AL: "Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors", LEUKEMIA 2002 UNITED KINGDOM, vol. 16, no. 9, 2002, pages 1589 - 1595, XP002346292, ISSN: 0887-6924 *
DUMENIL G ET AL: "Interferon [alpha] inhibits a Src-mediated pathway necessary for Shigella- induced cytoskeletal rearrangements in epithelial cells", JOURNAL OF CELL BIOLOGY 16 NOV 1998 UNITED STATES, vol. 143, no. 4, 16 November 1998 (1998-11-16), pages 1003 - 1012, XP002331178, ISSN: 0021-9525 *
HUANG M ET AL: "Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells", ONCOGENE 12 DEC 2002 UNITED KINGDOM, vol. 21, no. 57, 12 December 2002 (2002-12-12), pages 8804 - 8816, XP002346291, ISSN: 0950-9232 *
KRAKER A J ET AL: "Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3- d]pyrimidine tyrosine kinase inhibitors", BIOCHEMICAL PHARMACOLOGY 01 OCT 2000 UNITED STATES, vol. 60, no. 7, 1 October 2000 (2000-10-01), pages 885 - 898, XP002346293, ISSN: 0006-2952 *
QIE L ET AL: "Herpes Simplex Virus Entry Is Associated with Tyrosine Phosphorylation of Cellular Proteins", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 256, no. 2, 10 April 1999 (1999-04-10), pages 220 - 227, XP004439971, ISSN: 0042-6822 *
SELBACH M ET AL: "Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY 01 MAR 2002 UNITED STATES, vol. 277, no. 9, 1 March 2002 (2002-03-01), pages 6775 - 6778, XP002331179, ISSN: 0021-9258 *
TANG P ET AL: "Listeria monocytogenes, an invasive bacterium, stimulates MAP kinase upon attachment to epithelial cells", MOLECULAR BIOLOGY OF THE CELL 1994 UNITED STATES, vol. 5, no. 4, 1994, pages 455 - 464, XP002331177, ISSN: 1059-1524 *
VANICHKIN A ET AL: "LATE ADMINISTRATION OF A LIPOPHILIC TYROSINE KINASE INHIBITOR PREVENTS LIPOPOLYSACCHARIDE AND ESCHERICHIA COLI-INDUCED LETHAL TOXICITY", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 173, no. 4, April 1996 (1996-04-01), pages 927 - 933, XP002048356, ISSN: 0022-1899 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217033B2 (en) 2007-01-19 2012-07-10 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US8809322B2 (en) 2007-01-19 2014-08-19 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent

Also Published As

Publication number Publication date
EP1725295A2 (en) 2006-11-29
US20110281867A1 (en) 2011-11-17
EP2233174B1 (en) 2016-07-20
DE602005023587D1 (en) 2010-10-28
US8765777B2 (en) 2014-07-01
AU2005209231A1 (en) 2005-08-11
ATE481134T1 (en) 2010-10-15
CA2554201A1 (en) 2005-08-11
CA2554201C (en) 2015-04-14
EP2260849A1 (en) 2010-12-15
AU2005209231B8 (en) 2011-07-28
EP1725295B1 (en) 2010-09-15
JP5520433B2 (en) 2014-06-11
JP2007518810A (en) 2007-07-12
EP2233174A1 (en) 2010-09-29
AU2005209231B2 (en) 2011-03-17
WO2005072826A2 (en) 2005-08-11
JP2010202674A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
ATE481134T1 (en) COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS
EP2452935A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
MX2010002318A (en) 2,3-substituted azaindole derivatives for treating viral infections.
EP2687533A3 (en) Acrylamide derivatives as FAB I inhibitors
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2007130655A3 (en) Phage derived antimicrobial activities
MX349718B (en) Antimicrobial compounds and methods of making and using the same.
ZA200701629B (en) Gyrase inhibitors and uses thereof
MY176900A (en) Antimicrobial compounds and methods of making and using the same
WO2008082692A3 (en) Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
MX2010006203A (en) Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases.
MX2009009761A (en) Compositions and kits for treating influenza.
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
PH12015502375A1 (en) Antimicrobial compounds and methods of making and using the same
WO2008133734A3 (en) Method and compositions for treating hiv infections
WO2010032011A8 (en) Anti-fungal therapy
WO2010052575A3 (en) Ngna compositions and methods of use
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2554201

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006551238

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005209231

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005705915

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005209231

Country of ref document: AU

Date of ref document: 20050120

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005209231

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005705915

Country of ref document: EP